Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pracinostat PK with CYP Inhibitors in Healthy Subjects
NCT02118909Phase 1Completed
- Sponsor
- Helsinn
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pracinostat in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (2 arms), sponsored by Helsinn. Primary endpoint: Peak Plasma Concentration at 96 hours. Started May 2014; status: completed.
02
Drugs
pracinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT02118909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118909.